[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368735-105":59,"doc-detail-368735-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-immunomodulatory-role-of-tumor-initiating-cells-in-digestive-system-tumors-from-mechanisms-to-therapy","The immunomodulatory role of tumor-initiating cells in digestive system tumors - from mechanisms to therapy","","Targeting tumor-initiating cells (TICs) in digestive system tumors is presented as a feasible way to strengthen cancer immunotherapy. TICs exhibit stem cell-like traits that drive tumor heterogeneity, recurrence, and resistance to conventional medicines, weakening treatment outcomes. This review summarizes TIC features across colorectal, pancreatic, liver, and gastric cancers, detailing immune-evasion routes involving tumor microenvironment changes, reduced immunogenicity, and immune checkpoint molecule expression. It also discusses therapeutic options such as differentiation strategies, pathway inhibition, immune recognition enhancement, and combination approaches including adoptive cell therapy, TIC-targeted regimens, and immune checkpoint inhibitors, while addressing heterogeneity and immune escape challenges requiring more clinical validation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-immunomodulatory-role-of-tumor-initiating-cells-in-digestive-system-tumors-from-mechanisms-to-therapy/368735/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-immunomodulatory-role-of-tumor-initiating-cells-in-digestive-system-tumors-from-mechanisms-to-therapy/368735.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are tumor-initiating cells (TICs) considered important for digestive system cancer immunotherapy?","Question",{"text":113,"@type":114},"TICs have stem cell-like properties that can promote tumor heterogeneity, recurrence, and resistance to conventional medicines, thereby impairing treatment outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What mechanisms help TICs evade immune recognition?",{"text":118,"@type":114},"The review highlights immune-evasion mechanisms involving altered tumor microenvironment, decreased immunogenicity, and immune checkpoint molecule expression.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic strategies are proposed to target TICs?",{"text":122,"@type":114},"Strategies include differentiation therapies, inhibiting specific signaling pathways, enhancing immune recognition via advanced immunotherapeutic approaches, and considering combination therapy such as adoptive cell therapies, TIC-targeted strategies, and immune checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368735,1790810438,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 24 July 2025  \nDOI 10.3389/fimmu.2025.1621464  \nOPEN ACCESS  \nEDITED BY  \nChen Yang,  \nSouthern Medical University, China  \nREVIEWED BY  \nSenlian Hong,  \nPeking University, China Feng Chen,  \nWenzhou Medical University, China  \n*CORRESPONDENCE  \nKun-hua Wang  \n[wangkunhua1964@126.com](wangkunhua1964@126.com)[ ](wangkunhua1964@126.com)Fang Huang  \n [hfang@ynu.edu.cn](hfang@ynu.edu.cn)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 01 May 2025  \nACCEPTED 08 July 2025  \nPUBLISHED 24 July 2025  \nCITATION  \nZhang Z-y, Zhang X-f, Xu C-h, Wang K-h and Huang F (2025) The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy.  \nFront. Immunol. 16:1621464 .  \ndoi: 10.3389/fimmu.2025.1621464  \nCOPYRIGHT  \n© 2025 Zhang, Zhang, Xu, Wang and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe immunomodulatory role of tumor-initiating cells in digestive system tumors:  \nfrom mechanisms to therapy  \nZun-yue Zhang 1,2†, Xin-feng Zhang 3†, Cong-hui Xu 1,2, Kun-hua Wang 2* and Fang Huang 1*  \n1School of Medicine, Yunnan University, Kunming, China, 2Yunnan Technological Innovation Centre of Drug Addiction Medicine, Yunnan University, Kunming, China, 3 Department of Gastrointestinal and Hernia Surgery, The First Afﬁliated Hospital of Kunming Medical University, Kunming, China  \nTargeting tumor-initiating cells (TICs) in digestive system tumors is a feasible strategy to boost the effectiveness of cancer immunotherapy. Because of their stem cell-like properties, TICs can cause tumor heterogeneity, recurrence, and resistance to conventional medicines, which can seriously impair treatment outcomes. This review discusses the unique features of TICs inside various digestive system tumors, such as colorectal, pancreatic, liver, and gastric cancers. We look at the mechanisms that TICs evade immune recognition, including altered tumor microenvironment, decreased immunogenicity, and immune checkpoint molecule expression. Furthermore, we highlight potential strategies for TICs, such as differentiation therapies, inhibiting certain signaling pathways, and enhancing immune recognition through advanced immunotherapeutic approaches. The analysis also examines the potential for combination therapy, which include adoptive cell therapies, TIC-targeted strategies, and immune checkpoint inhibitors. Lastly, we address the challenges presented by TIC heterogeneity and immune escape mechanisms, emphasizing the need for more clinical research to back up these innovative tactics. All things considered, TIC targeting is a signiﬁcant method to improve immunotherapy ’s efﬁcacy in treating digestive system cancers, which will ultimately help patients.  \nKEYWORDS  \ntumor-initiating cells (TICs), digestive system tumors, immunotherapy, tumor microenvironment, immune checkpoints, combination therapy, differentiation therapy  \nIntroduction  \nAlong with the great majority of non-tumorigenic cells, some tumors have a little number of cells that have the ability to self-renew and start new tumors. Tumor-initiating cells (TICs), also called cancer stem cells (CSCs) or CSC-like cells, are a group of cells that can produce diverse cell populations that closely mimic the original tumor’s makeup (1) .  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nTICs, a subset of cells within malignancies, may arise from alterations in progenitor or normal stem cells or from genetic defects. Because of their similar ability to differentiate into diverse lineages, T","cbCaiuhSNPxGAFGj","https://ap.wps.com/l/cbCaiuhSNPxGAFGj","pdf",2427534,15,"English","# Introduction\n# Tumor-initiating cells (TICs) and origins\n# Differences between TICs and normal stem cells\n# TICs as drivers of tumor genesis, growth, recurrence\n# Immune evasion mechanisms in digestive system cancers\n# Therapeutic strategies and combination therapy\n# Challenges and future clinical directions","[{\"question\":\"Why are tumor-initiating cells (TICs) considered important for digestive system cancer immunotherapy?\",\"answer\":\"TICs have stem cell-like properties that can promote tumor heterogeneity, recurrence, and resistance to conventional medicines, thereby impairing treatment outcomes.\"},{\"question\":\"What mechanisms help TICs evade immune recognition?\",\"answer\":\"The review highlights immune-evasion mechanisms involving altered tumor microenvironment, decreased immunogenicity, and immune checkpoint molecule expression.\"},{\"question\":\"What therapeutic strategies are proposed to target TICs?\",\"answer\":\"Strategies include differentiation therapies, inhibiting specific signaling pathways, enhancing immune recognition via advanced immunotherapeutic approaches, and considering combination therapy such as adoptive cell therapies, TIC-targeted strategies, and immune checkpoint inhibitors.\"}]","The immunomodulatory role of tumor-initiating cells in digestive system tumors - from mechanisms to therapy | PDF",1790178255,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08a61d55471a9d6e0ad0b3467f3e987f.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b6a6bf90c13712114314042c4998db2.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d421aed7b953171180600e77ef98c76.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13cbce5b772a2d1e53596fa344207e4a.webp",980,1385]